S.C. Medicina Nucleare E Terapia Radiometabolica, INT IRCCS Fondazione G. Pascale, Naples, Italy.
S.C. Epidemiologia E Biostatistica, INT IRCCS Fondazione G. Pascale, Naples, Italy.
Eur J Nucl Med Mol Imaging. 2023 May;50(6):1753-1764. doi: 10.1007/s00259-023-06112-8. Epub 2023 Jan 23.
The role of internal dosimetry is usually proposed for investigational purposes in patients treated by RLT, even if its application is not yet the standard method in clinical practice. This limited use is partially justified by several concomitant factors that make calculations a complex process. Therefore, simplified dosimetry protocols are required.
In our study, dosimetric evaluations were performed in thirty patients with NENs who underwent RLT with [Lu]Lu-DOTATATE. The reference method (M0) calculated the cumulative absorbed dose performing dosimetry after each of the four cycles. Obtained data were employed to assess the feasibility of simplified protocols: defining the dosimetry only after the first cycle (M1) and after the first and last one (M2).
The mean differences of the cumulative absorbed doses between M1 and M0 were - 10% for kidney, - 5% for spleen, + 34% for liver, + 13% for red marrow, and + 37% for tumor lesions. Conversely, differences lower than ± 10% were measured between M2 and M0.
Cumulative absorbed doses obtained with the M2 protocol resembled the doses calculated by M0, while the M1 protocol overestimated the absorbed doses in all organs at risk, except for the spleen.
内部剂量学的作用通常是为接受 RLT 治疗的患者的研究目的而提出的,即使其应用尚未成为临床实践中的标准方法。这种有限的应用部分是由几个伴随因素所证明的,这些因素使得计算成为一个复杂的过程。因此,需要简化的剂量学方案。
在我们的研究中,对 30 名接受 [Lu]Lu-DOTATATE 治疗的神经内分泌肿瘤患者进行了剂量学评估。参考方法(M0)在完成四个周期中的每一个周期后进行剂量学计算以评估累积吸收剂量。获得的数据用于评估简化方案的可行性:仅在第一周期(M1)和第一和最后一个周期后(M2)进行剂量学定义。
M1 和 M0 之间累积吸收剂量的平均差异为:肾脏为 -10%,脾脏为 -5%,肝脏为 +34%,红骨髓为 +13%,肿瘤病变为 +37%。相反,M2 和 M0 之间的差异低于±10%。
M2 方案获得的累积吸收剂量与 M0 计算的剂量相似,而 M1 方案除了脾脏之外,在所有危险器官中都高估了吸收剂量。